Zhejiang Int'l Group Co

Zhejiang Int'l Group Co Capital Expenditures

The Capital Expenditures (CapEx) of Zhejiang Int'l Group Co (000411.SZ) as of Oct 21, 2026 is -237.15 M CNY. In the previous year, Capital Expenditures (CapEx) was -279.91 M CNY — a change of -15.28% (higher).

Capital Expenditures

-237.15 MCNY

YoY

-15.28%

Last updated:

Capital Expenditures (CapEx) of Zhejiang Int'l Group Co is 2025 -237.15 M CNY. Capital Expenditures (CapEx) of Zhejiang Int'l Group Co was 2024 -279.91 M CNY. It decreases by -15.28% higher compared to the previous year.

The Zhejiang Int'l Group Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-113.87 M CNY
Jan 1, 2019
-137.07 M CNY
Jan 1, 2020
-178.48 M CNY
Jan 1, 2021
-189.09 M CNY
Jan 1, 2022
-107.36 M CNY
Jan 1, 2023
-168.36 M CNY
Jan 1, 2024
-279.91 M CNY
Jan 1, 2025
-237.15 M CNY
The Zhejiang Int'l Group Co Capital Expenditures history
YEARCapital ExpendituresYoY
-237.15 MCNY-15.28%
-279.91 MCNY+66.25%
-168.36 MCNY+56.82%
-107.36 MCNY-43.22%
-189.09 MCNY+5.94%
-178.48 MCNY+30.22%
-137.07 MCNY+20.37%
-113.87 MCNY+27.11%
-89.59 MCNY-4.20%
-93.51 MCNY-40.40%
-156.89 MCNY+103.92%
-76.94 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

Capital Expenditures (CapEx) of Zhejiang Int'l Group Co is -237.15 M CNY in 2025.

Capital Expenditures (CapEx) of Zhejiang Int'l Group Co changed from -279.91 M CNY to -237.15 M CNY, representing a -15.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Zhejiang Int'l Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co